Conflict of interest
Pierre
ACP reports consultancy roles with BMS, Merck, Replimune and Regeneron and participation in a speakers bureau for BMS; MRM reports grants to his institution in relation to clinical studies from Roche, AstraZeneca, GSK, Immunocore and GRAIL; study fees to his institution from Novartis, Pfizer, Merck/MSD, and Regeneron; personal fees and other study fees to his institution from BMS, advisory board associated personal fees and study fees to his institution from BiolineRx; study fees to his institution from Replimune and advisory board participation (unremunerated); PL reports personal fees for advisory board or speakers bureau from BMS, Pierre Fabre, MSD, Novartis, Ultimovacs, Melagenix, Skyline Diagnostics and research funding from BMS and Pierre Fabre; JL reports institutional research support from BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and Aveo; grants from Achilles Therapeutics, BMS, MSD, Nektar Therapeutics, Novartis, Pfizer, Roche, Immunocore, Aveo and Pharmacyclics; personal consulting fees from iOnctura, Apple Tree, Merck, BMS, Eisai, Debiopharm and Incyte; honoraria for lectures or presentations from Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare Research, Royal College of General Practitioners, VJOncology, Agence Unik, BMS and Immatics, and support for attending meetings and/or travel from Pierre Fabre, Roche, GSK and Immatics. JQ and EB are employees of Day One Biopharmaceuticals. AJO reports personal fees from advisory boards including Merck, BMS, Pfizer, Takeda, Novartis, Eisai, Nektar and InstilBio; institution research support from Adaptimmune, Alkermes, Amgen, Antegene, Astellas, BMS, Checkmate, Eutilex, Fate therapeutics, Gan & Lee, GlycoNex, InstilBio, Intensity, Kadmon, Kartos, Kezar, Kinnate, Nektar, OncoSec, Regeneron, Shionogi, Sound Biologics, Sumitomo Dainippon, Takeda, and Targovax. Other authors did not declare a conflict of interest.